Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults
A Randomized, Double-blind, Active Comparator, Phase I/Ⅱa Clinical Trial to Assess the Safety and Immunogenicity of the 'IL-YANG Flu Vaccine Quadrivalent Inj.' in Healthy Korean Adult Subjects
研究概览
详细说明
This is a randomized, double-blind, active-controlled, phase I/Ⅱa clinical trial.
During the Part A phase, all safety data collected from the 12 subjects enrolled in the Part A phase will be analyzed to determine the safety and tolerability of the investigational product, which should include any solicited and unsolicited adverse drug reactions occurring for the first 7 days after vaccination and any adverse events occurring for 28 days after vaccination. Antibody titer test will be also performed to evaluate the efficacy (immunogenicity) of the investigational product. During the Part B phase, a total of 72 subjects will be enrolled, and all safety data (including all adverse events) and immunogenicity data will be analyzed.
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Healthy men and women 19 to < 65 years of age at screening
- Body weight within ±20% of ideal body weight at screening
- Women of childbearing potential must have a negative serum beta-hCG at visit 2; and agree to use a proper contraceptive method for 1 month after vaccination (starting from 3 months before screening), using a medication or device that does not have any drug-interaction with the investigational product.
- Subjects with no congenital or chronic disease who were considered suitable for the study after screening assessments (investigator's opinion, medical history, physical examination, laboratory test, chest X-ray, and ECG) conducted no later than 28 days prior to vaccination
- Subjects who were given, and fully understood, the information about the study, and have provided voluntary written informed consent to participate in the study and to comply with all applicable study requirements
Exclusion Criteria:
- Subject with known allergy to eggs, chicken, or any components of the investigational product
- Subjects who had received an influenza vaccine within the last 6 months prior to study entry
- Subjects who have known or suspected infection with HAV, HBV, HCV, HIV or VDRL
- Subjects who have concurrent or a past history of, immune deficiency disease
- Subject with a history of Guillain-Barre syndrome
- Subject with hemophilia or thrombocytopenia or being treated with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection
- Subjects with known allergy to a drug, food or latex, who had a history of anaphylaxis
- Subjects who had an acute fever with body temperature > 38.0 Cº within 72 hours prior to administration of the investigational product or symptoms of suspected acute disease within 14 days prior to administration of the investigational product
- Subjects who had received another vaccine within 28 days before administration of the investigational product or are planning to receive another vaccine during the study.
- Subjects who had participated in another clinical trial within the 30 days before administration of the investigational product.
- Subjects who had previously received blood-derived products (including immunoglobulin) within the last 3 months prior to administration of the Investigational product, or are scheduled to receive a treatment with blood-derived products during the study
- Subjects who had received, or are scheduled to receive, systemic immunosuppressive therapy, radiation therapy or high-dose steroid therapy within the last 6 months prior to administration of the study
- Subjects with a history of drug abuse within the last 6 months prior to vaccination, or is suspected of drug abuse
- Subjects with excessive consumption of caffeine, alcohol, or tobacco
- Subjects with other clinically significant medical or psychiatric illness who in the investigator's opinion, are not be suitable for the study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:IL-YANG Flu Vaccine QIV 0.5mL
A single 0.5mL dose administrated as an intramuscular injection.
|
|
有源比较器:IL-YANG Flu Vaccine TIV 0.5mL
A single 0.5mL dose administrated as an intramuscular injection.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Seroconversion Rate
大体时间:28 days
|
Percentage of subjects achieving seroconversion* for HI antibody after vaccination
|
28 days
|
Seroprotection Rate
大体时间:28 days
|
Percentage of subjects achieving seroprotection* for HI antibody after vaccination
|
28 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
GMR
大体时间:28 days
|
Geometric Mean Ratio of post vaccination HI geometric mean titers
|
28 days
|
GMT
大体时间:28 days
|
Geometric Mean Titer of post vaccination HI geometric mean titers
|
28 days
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.